Glenmark Farmaceutica’s three respiratory products  from Novartis

Glenmark Farmaceutica’s three respiratory products from Novartis

June 24, 2019 260

Indian-based Glenmark Pharmaceuticals’ Brazilian subsidiary has entered into an exclusive partnership agreement with Novartis Biosciences. Novartis' role surrounds three of Glenmark Farmacêutica’s respiratory products indicated for the treatment of the chronic obstructive pulmonary disease (COPD) symptoms.

 

The products involved in the agreement are Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (a combination of Indacaterol and Glycopyrronium), which are indicated for relief of symptoms in adults with COPD.

Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals, said: “This arrangement with a leading global pharmaceutical company will strengthen our respiratory franchise in Brazil.”

Under the terms of the agreement, Novartis remains the holder of the registration of these medicines and will be responsible to manufacture them with all technical excellence in line with its global commitment to quality, effectiveness and safety.

Glenmark will be responsible for promoting, commercialising and distributing of these products in Brazil when the agreement comes into effect on 1 July 2019 onwards.

 

 

Information source: here 

Block ?

If this page is in your subscriptions, then it will be removed. You will not see this page. If you want to unblock a user, go to the settings, the list of blocked users and click unblock

Complain

The user will not know who exactly sent the complaint

Delete Company

The user will not know who exactly sent the complaint

Notifications

You Have 112 readed notifications

CHATS

Select chat category

×